Ionis Pharmaceuticals Sees Price Target Rise to $77 Amid Analyst Upgrades

Ionis Pharmaceuticals (NASDAQ: IONS) has experienced a notable increase in its stock price target, rising from $73.00 to $77.00 according to a report released by analysts at Stifel Nicolaus. This revised target suggests a potential downside of approximately 5.06% from the company’s current trading price. Stifel Nicolaus currently maintains a “hold” rating on the stock.

The upward revision from Stifel Nicolaus is part of a broader trend, as several other financial institutions have also reassessed their positions on Ionis Pharmaceuticals. For instance, HC Wainwright raised its price target from $100.00 to $110.00, designating the stock with a “buy” rating in a report dated November 10, 2023. Similarly, TD Cowen reiterated a “buy” rating in a note published on December 3, 2023, while Bank of America increased its target from $86.00 to $97.00, also assigning a “buy” rating.

Morgan Stanley set a target price of $95.00 and categorized the stock as “overweight.” Additionally, Raymond James Financial updated its rating to “strong-buy,” raising its target price from $85.00 to $89.00.

Analyst sentiment towards Ionis Pharmaceuticals is generally positive, with one analyst issuing a “strong buy” recommendation, 16 analysts giving a “buy” rating, three assigning a “hold” rating, and one issuing a “sell” rating. According to data from MarketBeat, the consensus rating for Ionis Pharmaceuticals stands at “Moderate Buy” with a consensus target price of $88.15.

Financial Performance and Earnings Overview

Ionis Pharmaceuticals last reported its earnings on February 25, 2024, revealing a loss of $1.41 per share for the quarter. This figure fell short of analysts’ expectations, which had estimated a loss of $1.23 per share. The company noted a negative net margin of 26.45% and a return on equity of -44.26%. Despite these challenges, Ionis reported revenues of $203.00 million for the quarter, surpassing forecasts of $156.07 million. This represents a decline of 10.6% compared to the same quarter in the previous year, during which the company posted earnings of ($0.66) per share.

Looking ahead, analysts project that Ionis Pharmaceuticals will record an earnings per share (EPS) of -3.5 for the current fiscal year.

Insider Transactions and Institutional Interest

In recent insider trading, CEO Brett P. Monia sold 29,430 shares of the company’s stock on February 6, 2024, at an average price of $85.79, amounting to a total of $2,524,799.70. Following this transaction, Monia retained ownership of 254,497 shares valued at approximately $21,833,297.63, reflecting a 10.37% decrease in his position. The sale was disclosed in a filing with the Securities and Exchange Commission.

Additionally, Executive Vice President Eugene Schneider sold 6,179 shares on January 30, 2024, for $515,637.55 at an average price of $83.45. This sale also represented an 8.14% reduction in his position. Over the past ninety days, insiders have sold a total of 464,579 shares valued at $37,630,193, with insiders currently holding 2.60% of the company’s stock.

Institutional investors have also shown significant activity in Ionis Pharmaceuticals. Notably, Capital World Investors increased its stake by 41.2% in the fourth quarter, now owning 17,961,299 shares valued at approximately $1.42 billion. Other firms, including Adage Capital Partners GP L.L.C. and Franklin Resources Inc., have also boosted their holdings significantly during this period.

Currently, institutional investors and hedge funds hold 93.86% of Ionis Pharmaceuticals’ stock, reflecting strong institutional confidence in the company’s future.

Ionis Pharmaceuticals, founded in 1989, is a biotechnology company specializing in RNA-targeted therapies aimed at modifying gene expression. The company utilizes proprietary antisense oligonucleotide (ASO) technology to inhibit or modify protein production linked to various diseases. Its diverse pipeline encompasses treatments for neurological disorders, cardiovascular diseases, metabolic conditions, and rare genetic disorders.